Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Biogen, Denali Terminate Parkinson’s Drug BIIB122 After Phase IIb LUMA Study Failure

Fineline Cube May 25, 2026
Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026

The National Medical Products Administration (NMPA) this week released the draft proposal “Appendix to the...

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) unveiled pivotal Phase III DIAMOND-2 trial results for Xuanfeining...

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299/MK-2010, a PD-1/VEGF bispecific antibody...

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026

Eli Lilly & Co. (NYSE: LLY) is reportedly engaged in advanced negotiations to acquire Kelonia...

Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026

AbbVie Inc. (NYSE: ABBV), the US pharmaceutical giant, has announced a strategic partnership with the...

Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026

Annoroad Gene Technology (Beijing) Co., Ltd., a leading Chinese provider of integrated life science sequencing...

Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a...

Company Drug

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen

Fineline Cube Apr 17, 2026

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced that its in-house developed isophane protamine recombinant...

Company Drug

Hansoh Pharma’s B7-H3 ADC HS-20093 Secures Fourth NMPA Breakthrough Therapy Designation for NSCLC Combination Therapy

Fineline Cube Apr 17, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) has announced that its investigational antibody-drug conjugate (ADC),...

Company Drug

Hengrui Pharma’s Nectin-4 ADC SHR-A2102 Granted Second NMPA Breakthrough Therapy Designation for Cervical Cancer

Fineline Cube Apr 17, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 therapeutic...

Company

Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices

Fineline Cube Apr 17, 2026

Abbott Laboratories (NYSE: ABT) announced its financial results for the first quarter of 2026, reporting...

Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026

Tigermed Consulting Co., Ltd. (SHE: 300347), a leading Chinese Contract Research Organization (CRO), has announced...

Company Deals

Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir

Fineline Cube Apr 17, 2026

Amoytop Biotech Co., Ltd. (SHA: 688278), a leading Chinese biopharmaceutical company, has entered into a...

Company Drug

Changchun High & New Tech Gains NMPA Clearance for GenSci136 Phase I/II Trial in Generalized Myasthenia Gravis

Fineline Cube Apr 17, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a major Chinese biopharmaceutical company,...

Company Deals

Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy’s Molteni Farmaceutici

Fineline Cube Apr 17, 2026

Yifan Pharmaceutical Co., Ltd. (SHE: 002019), a leading Chinese biopharmaceutical company, has announced a new...

Company Deals Digital

GE HealthCare and DeepHealth Expand Global Partnership to Advance AI-Powered Mammography Solutions

Fineline Cube Apr 17, 2026

GE HealthCare Technologies Inc. (NASDAQ: GEHC), a global leader in medical technology and life sciences,...

Company Deals

Betta Pharmaceuticals Partners with Eversana for US Commercialization of Ensartinib in ALK+ NSCLC

Fineline Cube Apr 17, 2026

Betta Pharmaceuticals Co., Ltd. (SHE: 300558), a China-based oncology-focused biopharma company, has entered into a...

Company Deals

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio

Fineline Cube Apr 17, 2026

Kailera Therapeutics, Inc. (NASDAQ: KLRA), a US-based biotech venture established in 2024 by China’s Jiangsu...

Company Drug

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients

Fineline Cube Apr 17, 2026

Hong Kong WinHealth Pharma Group announced that China’s National Medical Products Administration (NMPA) has granted...

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Fineline Cube Apr 16, 2026

RemeGen Ltd (HKG: 9995) has announced the receipt of USD 650 million in upfront payment...

Posts pagination

1 … 17 18 19 … 670

Recent updates

  • Hangzhou Diagens Secures NMPA Category III Approval for AI AutoVision Chromosome Karyotyping System
  • Biogen, Denali Terminate Parkinson’s Drug BIIB122 After Phase IIb LUMA Study Failure
  • Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma
  • Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer
  • Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Hangzhou Diagens Secures NMPA Category III Approval for AI AutoVision Chromosome Karyotyping System

Company Drug

Biogen, Denali Terminate Parkinson’s Drug BIIB122 After Phase IIb LUMA Study Failure

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.